Sam Brusco, Associate Editor05.23.24
Inari Medical has filed a patent infringement lawsuit against Imperative Care and Truvic Medical (collectively, “Truvic) in the U.S. District Court for the Northern District of California.
Inari is seeking injunctive relief and damages for the infringement. The company alleges that Truvic is infringing eight of its patents related to use of aspiration-based thrombectomy devices to treat pulmonary emboli and deep vein thrombosis.
Truvic products named in the lawsuit include the Symphony thrombectomy system.
“Inari was founded to improve patients’ lives using purpose-built innovation. Our mission depends on these innovations, and we are deeply committed to protecting our intellectual property rights,” said Drew Hykes, CEO of Inari Medical.
The offending Symphony thrombectomy system removes thrombus from peripheral vasculature using continuous aspiration. It’s indicated for removal of fresh, soft emboli and thrombi. Its mechanical assist has a helical design and it’s equipped with two flexible Symphony catheters.
Inari Medical’s FlowTriever retrieval/aspiration system is the first mechanical thrombectomy system to earn U.S. Food and Drug Administration (FDA) 510(k) clearance to treat pulmonary embolism. The FlowTriever system rapidly removes thrombi and offers immediate improvement of symptoms for patients suffering from acute pulmonary embolism, according to the company.
In November 2023, Inari enrolled the first patient in its PEERLESS II study to compare FlowTriever against anticoagulant therapy alone for intermediate-risk, acute pulmonary embolism.
Inari is seeking injunctive relief and damages for the infringement. The company alleges that Truvic is infringing eight of its patents related to use of aspiration-based thrombectomy devices to treat pulmonary emboli and deep vein thrombosis.
Truvic products named in the lawsuit include the Symphony thrombectomy system.
“Inari was founded to improve patients’ lives using purpose-built innovation. Our mission depends on these innovations, and we are deeply committed to protecting our intellectual property rights,” said Drew Hykes, CEO of Inari Medical.
The offending Symphony thrombectomy system removes thrombus from peripheral vasculature using continuous aspiration. It’s indicated for removal of fresh, soft emboli and thrombi. Its mechanical assist has a helical design and it’s equipped with two flexible Symphony catheters.
Inari Medical’s FlowTriever retrieval/aspiration system is the first mechanical thrombectomy system to earn U.S. Food and Drug Administration (FDA) 510(k) clearance to treat pulmonary embolism. The FlowTriever system rapidly removes thrombi and offers immediate improvement of symptoms for patients suffering from acute pulmonary embolism, according to the company.
In November 2023, Inari enrolled the first patient in its PEERLESS II study to compare FlowTriever against anticoagulant therapy alone for intermediate-risk, acute pulmonary embolism.